Rhumbline Advisers Pfizer Inc Transaction History

Rhumbline Advisers

$103 Billion
Q1 2024

A detailed history of Rhumbline Advisers transactions in Pfizer Inc stock. As of the latest transaction made, Rhumbline Advisers holds 9,993,551 shares of PFE stock, worth $280 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares

9,993,551

Previous 10,295,837 2.94%

Holding current value

$280 Million

Previous $296 Million 6.44%

% of portfolio

0.27%

Previous 0.31%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$25.89 - $29.73 $7.83 Million - $8.99 Million	-302,286 Reduced 2.94%	9,993,551 $277 Million
Q4 2023 Feb 08, 2024	SELL	$26.13 - $33.94 $3.34 Million - $4.33 Million	-127,657 Reduced 1.22%	10,295,837 $296 Million
Q3 2023 Nov 09, 2023	BUY	$32.09 - $37.51 $3.74 Million - $4.37 Million	116,428 Added 1.13%	10,423,494 $346 Million
Q2 2023 Aug 08, 2023	BUY	$36.12 - $41.79 $5.55 Million - $6.42 Million	153,664 Added 1.51%	10,307,066 $378 Million
Q1 2023 May 11, 2023	BUY	$39.39 - $51.28 $15.4 Million - $20 Million	390,520 Added 4.0%	10,153,402 $414 Million

Q4 2022 Feb 14, 2023	BUY	$41.75 - $54.5 $15.8 Million - $20.6 Million	377,345 Added 4.02%	9,762,882 $500 Million
Q3 2022 Nov 10, 2022	BUY	$43.76 - $53.42 $5.27 Million - $6.43 Million	120,422 Added 1.3%	9,385,537 $411 Million
Q2 2022 Aug 11, 2022	BUY	$46.53 - $55.17 $23.7 Million - $28.1 Million	509,399 Added 5.82%	9,265,115 $486 Million
Q1 2022 May 12, 2022	BUY	$45.75 - $56.69 $6.78 Million - $8.4 Million	148,187 Added 1.72%	8,755,716 $453 Million
Q4 2021 Feb 10, 2022	BUY	$41.32 - $61.25 $1.43 Million - $2.13 Million	34,698 Added 0.4%	8,607,529 $508 Million
Q3 2021 Nov 12, 2021	BUY	$39.25 - $50.42 $7.42 Million - $9.53 Million	188,970 Added 2.25%	8,572,831 $369 Million
Q2 2021 Aug 05, 2021	SELL	$35.91 - $40.68 $21.8 Million - $24.7 Million	-608,030 Reduced 6.76%	8,383,861 $328 Million
Q1 2021 May 06, 2021	SELL	$33.49 - $37.77 $14.7 Million - $16.6 Million	-439,043 Reduced 4.66%	8,991,891 $326 Million
Q4 2020 Feb 10, 2021	BUY	$33.47 - $42.56 $1.66 Million - $2.11 Million	49,552 Added 0.53%	9,430,934 $347 Million
Q3 2020 Nov 12, 2020	BUY	$31.75 - $37.25 $2.89 Million - $3.39 Million	90,965 Added 0.98%	9,381,382 $344 Million
Q2 2020 Aug 13, 2020	BUY	$30.12 - $36.54 $13.8 Million - $16.8 Million	458,713 Added 5.19%	9,290,417 $304 Million
Q1 2020 May 06, 2020	BUY	$27.03 - $38.62 $1.5 Million - $2.15 Million	55,609 Added 0.63%	8,831,704 $288 Million
Q4 2019 Feb 05, 2020	BUY	$32.92 - $37.36 $260,298 - $295,405	7,907 Added 0.09%	8,776,095 $344 Million
Q3 2019 Oct 23, 2019	SELL	$32.49 - $42.13 $5.6 Million - $7.27 Million	-172,448 Reduced 1.93%	8,768,188 $315 Million
Q2 2019 Aug 14, 2019	SELL	$36.98 - $41.52 $10.3 Million - $11.6 Million	-278,970 Reduced 3.03%	8,940,636 $387 Million
Q1 2019 May 01, 2019	SELL	$37.5 - $41.2 $8.64 Million - $9.49 Million	-230,278 Reduced 2.44%	9,219,606 $392 Million
Q4 2018 Jan 31, 2019	BUY	$38.47 - $43.86 $4.37 Million - $4.98 Million	113,506 Added 1.22%	9,449,884 $412 Million
Q3 2018 Nov 07, 2018	SELL	$34.47 - $41.81 $5.28 Million - $6.4 Million	-153,124 Reduced 1.61%	9,336,378 $411 Million
Q2 2018 Aug 06, 2018	SELL	$32.98 - $35.16 $6.62 Million - $7.05 Million	-200,605 Reduced 2.07%	9,489,502 $344 Million
Q1 2018 May 02, 2018	SELL	$31.91 - $37.02 $1.63 Million - $1.89 Million	-50,995 Reduced 0.52%	9,690,107 $344 Million
Q4 2017 Feb 09, 2018	BUY	$33.26 - $35.29 $8.55 Million - $9.07 Million	256,949 Added 2.71%	9,741,102 $353 Million
Q3 2017 Nov 06, 2017	BUY	$31.0 - $34.15 $294 Million - $324 Million	9,484,153	9,484,153 $339 Million

Others Institutions Holding PFE

# of Institutions

3,159

Shares Held

3.68B

Call Options Held

67.4M

Put Options Held

113M

View Full List

About PFIZER INC

Ticker PFE
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 5,612,349,952
Market Cap $157B
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...

More about PFE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Pfizer Inc Transaction History